The Global Health Body Sounds Concern Over Severe Shortage of Obesity Injections
Less than 10% of individuals eligible to benefit from obesity jabs including Wegovy can access them, caution the global health agency as it releases its initial advice on the medications.
With over a billion people worldwide now living with obesity, it is urging increased and just access to these injectable treatments.
Based on projections, over two billion are projected to be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant hurdles to broad availability to the injections that can aid individuals in losing considerable weight, explains the body.
Skinny Jab Scarcity
Despite the present most optimistic scenario, the manufacturing of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, according to the WHO.
The guideline encourages nations and manufacturers to expand access, through strategies including voluntary licensing.
A patent on a key compound – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.
How Obesity Injections Operate
The injections replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so users reduce food intake.
Individuals typically see weight reduction after several weeks of starting on the weekly injections.
Studies indicates users may see weight return a year later of discontinuing the treatment, as their normal food cravings return.
To be carrying excess weight elevates your risk for contracting medical conditions, including diabetes, heart disease, stroke, and certain cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
